Danish Economy Bounces Back to Growth Led by Drugmakers
Gross domestic product, adjusted for seasonal swings, rose 1.3% from the previous three months, when it contracted 1.3%, Statistics Denmark said on Wednesday in a preliminary reading. The growth in the second quarter was driven by a bounce-back among drugmakers, with increased oil extraction also contributing, the statistics agency said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
China's extension of EU dairy import probe linked to September talks
China will not conclude its anti-dumping investigation into EU dairy imports until at least early next year as talks are set to continue in September. In response to China's decision this week to extend its probe to February, the European Dairy Association (EDA) said it was not surprised by the decision given Chinese officials are due to make 'technical visits' to Belgium and the Netherlands next month, as well as hold talks with the European Commission (EC). China kicked off its investigation in August last year to ascertain whether the EU was guilty of exporting dairy products to the Asian country at prices that put local producers at an unfair advantage. The probe followed similar enquiries launched by China for pork and brandy shipped from the European trading bloc that commenced in June and January of 2024, respectively. The trade spat with China was sparked by the EU threatening to impose tariffs on imports of Chinese battery electric vehicles (BEV), with the EC claiming 'unfair subsidisation' by its Chinese counterparts that risked 'causing a threat of economic injury' to local manufacturers. Xinhua, China's state-run news agency and official government mouthpiece, reported on Monday (18 August) that the Ministry of Commerce had extended its investigation into 'certain dairy products' from the EU to February The news service, citing a Ministry statement, said the extension was due to the 'complexity of the case'. Similar language emerged from the EDA. Its Secretary General Alexander Anton said in a statement: 'This highlights the increasingly complex dynamics of global dairy trade and has required coordinated responses from the industry and policymakers, and EDA will continue to work closely with the EU Commission and the 'sampled' dairies that are most involved in the process.' In October last year, China's Ministry of Commerce identified Dutch dairy giant FrieslandCampina, Elvir (France) Co. and Sterilgarda Alimenti in Italy as three EU companies that would be subject to a sampling exercise as part of its anti-dumping probe. Meanwhile, the EC took its case to the World Trade Organization (WTO) last September under a 'commitment to firmly defend the interests of the EU dairy industry and the Common Agricultural Policy against abusive proceedings'. Anton at the EDA said today (20 August) in the statement, when asked for comment and an update on those proceedings by Just Food: 'With that, for the very first time in such an early state of the procedure, the EU has given a clear political sign to step up to defend our European interest. 'WTO procedures are not known for speed and so far, we have no signs for any progress at this level.' Just Food has asked the EC for an update on the status of proceedings regarding China's probe into dairy and pork imports from the bloc, and whether there has been any progress with the WTO. When China kicked off its dairy import investigation last August, Xinhua said the probe was launched on behalf of the Dairy Association of China and the China Dairy Industry Association. The news agency suggested at the time that the review would include fresh cheese, curd and blue cheese from the EU. It was expected that the enquiry would conclude on 21 August of this year but could be extended for six months 'under special circumstances'. "China's extension of EU dairy import probe linked to September talks" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
4 minutes ago
- Bloomberg
Brevan Howard's Digital Business CEO Gautam Sharma Departs Firm
Gautam Sharma, chief executive officer of the digital investment unit of Brevan Howard Asset Management has left after almost five years at the hedge fund firm. London-based Sharma went on leave earlier this year and won't be returning, according to people with knowledge of the matter. Brevan Howard doesn't plan to fill that role, said one of the people, who all asked not to be identified discussing private information.
Forbes
4 minutes ago
- Forbes
Viking Therapeutics: What's Happening With VKTX Stock?
Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk. Moreover, 28% of patients discontinued therapy due to side effects such as nausea and vomiting. Even so, we think the magnitude of the selloff looks somewhat overdone. We expand on this view in the sections below. If you're seeking upside with less volatility than a single stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P midcap indexes—with returns exceeding 91% since inception. Also, see – Oracle: ORCL Stock To $160? Pipeline Beyond VK2735: Multiple Shots on Goal Despite the setback, Viking still has several promising candidates that the market may be overlooking: Valuation Disconnect At $24 versus the $89 analyst average price target, Viking trades at a steep discount. While some targets will likely be revised lower, the size of the decline appears excessive for a company with no commercial revenue whose value is tied to a diversified pipeline rather than a single program. Of course, we could be wrong, especially if investors were primarily banking on the obesity pill as the core growth driver, in which case the stock could keep sliding despite pipeline breadth. The Verdict Surely, there is always a meaningful risk when investing in a single, or just a handful, of stocks. Consider the Trefis High Quality (HQ) Portfolio, which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index—less of a roller-coaster ride—as shown in HQ Portfolio performance metrics.
